Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-03-22
2011-03-22
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S489000, C424S490000, C424S493000
Reexamination Certificate
active
07910132
ABSTRACT:
A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
REFERENCES:
patent: 4206209 (1980-06-01), Kracauer et al.
patent: 4574080 (1986-03-01), Roswall et al.
patent: 4582835 (1986-04-01), Lewis et al.
patent: 5047244 (1991-09-01), Sanvordeker et al.
patent: 5112616 (1992-05-01), McCarty
patent: 5288497 (1994-02-01), Stanley et al.
patent: 5288498 (1994-02-01), Stanley et al.
patent: 5290561 (1994-03-01), Farhadieh et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5733571 (1998-03-01), Sackler
patent: 5762961 (1998-06-01), Roser et al.
patent: 5948389 (1999-09-01), Stein
patent: 5968547 (1999-10-01), Reder et al.
patent: 6759059 (2004-07-01), Pettersson et al.
patent: 6761910 (2004-07-01), Pettersson et al.
patent: 6974590 (2005-12-01), Pather et al.
patent: 746373 (2002-04-01), None
patent: 2274893 (1998-06-01), None
patent: 0 144 243 (1985-06-01), None
patent: 0 324 725 (1989-01-01), None
patent: 0 324 725 (1989-07-01), None
patent: 0 324 725 (1999-01-01), None
patent: 146824/85 (1985-08-01), None
patent: 06-065103 (1994-03-01), None
patent: 06-065103 (1994-03-01), None
patent: 500578/96 (1996-01-01), None
patent: 504189/96 (1996-08-01), None
patent: WO 90/04962 (1990-05-01), None
patent: WO 9004952 (1990-05-01), None
patent: WO 9004962 (1990-05-01), None
patent: WO 94/03186 (1994-02-01), None
patent: WO 94/06426 (1994-03-01), None
patent: WO 95/01782 (1995-01-01), None
patent: WO 9501782 (1995-01-01), None
patent: WO 97/15297 (1997-05-01), None
patent: WO 98/26763 (1998-06-01), None
patent: WO 9826763 (1998-06-01), None
patent: WO99/24023 (1999-05-01), None
patent: WO 9936071 (1999-07-01), None
Stanely et al (Oral Transmucosal Fentanyl Citrate (Lollipop) Premedication in Human Volunteers); Anesth Analg 1989; 69:21-7.
Kunz et al, Severe Episodic Pain: Management with SUblingual sufentamil, May 1993, Journal od Pain and Symptom Management, vol. 8, No. 4, p. 189.
Olav Gaserrod et al. “The Enhancement of the Bioadhesive Properties of Calcium Alginate Gel Beads by Coating With Chitosan”, International Journal of Pharmaceutics, vol. 175, 1998, pp. 237-246.
Dominique Duchene et al., “Bioadhesion of Solid Oral Dosage Forms, Why and How?”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 44, 1997, pp. 15-23.
M. Westerberg and C. Nystrom, “Physicochemical Aspects of Drug Release XVIII. The Use of a Surfactant AD a Disinterant for Improving Drug Dissolution Rate From Ordered Mixtures”, S.T.P. Pharma Sciences, vol. 3, No. 2, 1993, pp. 142-147.
Fine et al., An Open Label Study of Oral Transmucosal Fentanyl Citrate (OTFC) for the Treatment of Breakthrough Cancer Pain, 1991, Pain, 45, 149-153.
Farrar JT et al., “Oral Trans Fentanyl Citrate: Randomized, Double-Blinded, Placebo-Controlled Trail for Treatment of Breakthrough Pain in Cancer Patients,”, J Nati Cancer Inst (Unites States) Apr. 15, 1998, vol. 90, No. 8, pp. 611-616.
Weinberg et al., “Sublingual absorption of selected opioid analgesics”, Clinical Pharmacology and Therapeutics 44(3):335-342 (1988).
Nyström et al., “The use of ordered mixtures for improving the dissolution rate of low solubility compounds” J. Pharm. Pharmacol. 38:161-165 (1986).
Ciraulo et al. “Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials” Journal of Clinical Pharmacology 46:179-192 (2006).
Harris “Opportunities provided by the buccal and nasal administration of peptides” Minutes European Symposium on Buccal and Nasal Administration as an Alternative to Parenteral Administration. Paris, France, Dec. 10-11, 1991 pp. 204-225.
Lennernäs et al. “Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain” British Journal of Clinical Pharmacology 59(2):249-253 (2005).
Malmqvist et al. “Studies on direct compression of tablets. IX: The effect of scaling-up on the preparation of ordered mixtures in double-cone mixers” Acta Pharmaceutica Suecica 21: 21-30 (1984).
Taylan et al. “Design and evaluation of sustained-release and buccal adhesive propranolol hydrochloride tablets” Journal of Controlled Release 38:11-20 (1996).
Voorspoels et al. “Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs” Pharmaceutical Research 13(8):1228-1232 (1996).
Mashkovsky, MB, Medicaments, Moscow, “Meditsina”, 1985, part I, pp. 175-176.
The Lecture of Pharmacology, vol. 2, p. 236, Mar. 20, 1987.
Stanley et al., “Oral Transmucosal Fentanyl Citrate (Lollipop) Premedication in Human Volunteers”,Anesth. Analog., 69:21-27 (1989).
Website www.rxlist.com/duragesic-drug.htm; Duragesic (Fentanyl Transdermal) Drug Information: Uses, Side Effects, Drug Interactions, Apr. 23, 2009.
Shojaei, “Buccal Mucosa As a Route for Systemic Drug Delivery: A Review”, J Pharm. Pharaceut Sci (www.ualberta.ca/˜csps) 1 (1):15-30, 1998.
Rowland et al., Clinical Pharmacokinetics Concepts and Applications, 1995. pp. 110-130.
Mather, Clinical Pharmacokinetics of Fentanyl and its Newer Derivitives; Clinical Pharmacokintics 8: 422-446 (1983).
Bernards, Opioids in Pain Control, Basic and Clinical Aspects; 1999; p. 171.
Bogt et al., Pharmacokinetics and Haemodynamic Effects of ISDN Following Different Dosage Forms and Routes of Administration; Eur J Clin Pharmacol (1994) 46: 319-324.
Kroboth et al., Triazolam Pharmacokinetics After Intravenous, Oral, and Sublingual Administration; Journal of Clinical Psychopharmacology, 1995; vol. 15, pp. 259-262.
Stanley et al., “Novel Delivery Systems: Oral Transmucosal and Intranasal Transmucosal,”Journal of Pain and Symptom Management, vol. 7 No. 3, Apr. 1992.
Ashburn et al., “Oral Transmucosal Fentanyl Citrate for the Treatment of Breakthrough Cancer Pain: A Case Re-port,”Anesthesiology, 71:615-617, 1989.
Nystrom Christer
Pettersson Anders
Hartley Michael G
Orexo AB
Ryan Kromholz & Manion S.C.
Young Micah-Paul
LandOfFree
Pharmaceutical composition for the treatment of acute disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the treatment of acute disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of acute disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2733967